BACKGROUND: Observational data suggest that serum @entity1760 ( @entity4612 ) concentration is inversely related to @entity729 and @entity2742 among @entity1 with @entity454 ( @entity454 ). In recent years, there have been several case reports of @entity1272 due to use of proton-pump inhibitors (PPI), with the @entity1272 attributed to inappropriate gastrointestinal (GI) @entity4612 loss. We hypothesized that the tendency to GI @entity4612 loss is more common than is currently reported. Since @entity1 with @entity454 have little to no renal @entity4612 loss to affect serum @entity4612 concentration, dialysis @entity1 are an interesting population in whom to study the relationship between PPI use and serum @entity4612 levels. METHODS: Using a single-center cross-sectional design, we studied 155 prevalent hemodialysis (HD) patients. Serum @entity4612 concentration for each @entity1 was determined based on the mean of 3 consecutive serum @entity4612 levels drawn at 6  week intervals. PPI use at the time of the blood tests was documented. The relationship between PPI use and @entity4612 concentration was determined in unadjusted analyses, as well as after adjustment for age, gender, race, cause of @entity454 , @entity6 , time on HD and dialysate @entity4612 concentration. RESULTS: 55  % of @entity1 were on PPIs at the time of the study. The majority of @entity1 (62  %) used a dialysate @entity4612 (in mmol/L) of 0.5, and the remainder (38  %) used a dialysate @entity4612 of 0.375. Serum @entity4612 levels were significantly lower among PPI users vs. non-users (0.93 vs. 1.02  mmol/L, p   <   0.001). This finding persisted after stratifying for dialysate @entity4612 concentration, and after multivariable adjustment (p   <   0.001). In addition, more PPI users vs. non-users had a @entity4612 level   <   1  mmol/L (79  % vs. 43  %) and a @entity4612 level   <   0.8  mmol/L (16  % vs. 4  %). There was a non-significant trend toward increased time on PPI being associated with lower serum @entity4612 levels (p   =   0.067). CONCLUSION: Among HD @entity1 , PPI users have lower serum @entity4612 levels as compared with non-users. Further research is required to determine whether the magnitude of change in @entity4612 levels among PPI users is associated with adverse outcomes.

The relationship between proton pump inhibitor use and serum XXXX concentration among hemodialysis @entity1 : a cross-sectional study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4612 :: ('D008274', 'Chemical') :: ['Mg'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity1272 :: ('MESH:C537153', 'Disease') :: ['hypomagnesemia'] @entity729 :: ('MESH:D061205', 'Disease') :: ['vascular calcification'] @entity2742 :: ('MESH:D006961', 'Disease') :: ['hyperparathyroidism'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity1760 :: (MESH:D008274,Chemical) :: ['magnesium']
